CORT

Corcept Therapeutics Stock Analysis

AI Rating

Fair
  • Quality9/10
  • Growth↓ 2/10
  • Momentum↓ 0/10
Corcept Therapeutics sales and earnings growth
CORT Growth
Fair
  • Revenue Y/Y↑ 17.92%
  • EPS Y/Y↓ -26.47%
  • FCF Y/Y↑ 14.42%
Corcept Therapeutics gross and profit margin trends
CORT Profitability
Great
  • Gross margin ↑ 98.20%
  • EPS margin↑ 14.10%
  • ROIC↓ 11.20%
Corcept Therapeutics net debt vs free cash flow
CORT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 2.8

Corcept Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗